🇺🇸 US Stock Screener ← Switch market ⚡ HerAI

Creative Medical Technology Holdings, Inc. CELZ PHARMA

Healthcare · Biotechnology · United States
https://www.creativemedicaltechnology.com
Company Profile ↓
$1.08
-66.56% 1Y
Mkt Cap$7.12M
P/E-0.53
P/B0.78
52W High$5.59
52W Low$0.65
Book Value$1.33
EPS (TTM)$-2.05

Company Overview

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.16.

Recent Developments

  • Dec 2025 Revenue of $6.00K (-45.5% YoY); net profit $-6.00M.
  • Trailing 12 Months Year-on-year growth — revenue -45.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR -48.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-48.43%
1 Year:-45.45%

Stock Price Performance

1 Year:-66.56%
6 Months:-43.46%
3 Months:-50.22%
1 Month:-23.94%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 9% of range
$0.65 $5.59
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)47.30 · Neutral
Price Performance
1M-23.94%
3M-50.22%
6M-43.46%
1Y-66.56%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Revenue declined at -48.4% CAGR over 5 years.
  • Trading 80.7% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-0.53
Industry PE
24.83
Forward P/E
-1.23
PEG Ratio
-
Book Value
$1.33
Price to Book
0.78
P/S
2,285.42
EV/EBITDA
0.27
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-48.43%
Profit 5Y
-
Revenue (YoY)
-45.45%
Earnings (YoY)
-

Profitability & Returns

ROCE
-81.64%
ROE
-77.88%
ROA
-47.32%
Profit Margin
0.00%
Op Margin
-
Gross Margin
66.87%
EPS (Latest Qtr)
$-0.41
EPS (TTM)
$-2.05

Balance Sheet & Liquidity

Debt/Equity
0.16
Quick Ratio
12.65
Current Ratio
12.91
Debt
$14.19K
Total Assets
$9.38M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
0.53%
Chg in Prom Hold
-0.21%
FII / Inst Holding
5.66%
Chg in FII Hold
0.67%

Financial Snapshot

Enterprise Value
$7.12M
Total Revenue (TTM)
$3.00K
EBITDA
$-6.13M
Free Cash Flow
$-3.46M
Operating Cash Flow
$-5.90M
Shares Outstanding
6.59M
Gross Margin
66.87%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 CELZ Creative Medical Technology Holdings, Inc. PHARMA 1.08 -0.53 $7.12M 0.00% -81.64% -77.88% -48.43% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,123.91 37.80 $1.00T 0.60% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 269.12 31.22 $648.55B 1.98% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 248.78 70.48 $439.62B 2.78% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 148.46 118.77 $366.28B 2.31% - 6.96% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 400.84 25.74 $359.79B 2.47% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 137.70 20.80 $261.73B 3.36% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 160.04 23.99 $248.20B 2.00% 15.97% 21.96% 9.82% 45.96%
9 TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA 603.02 32.49 $222.97B 0.29% 8.14% 13.51% 8.81% 12.95%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2013Sep 2013Mar 2014Jun 2014Sep 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026Jun 2026
Revenue 000000000000009.60K4.80K52.40K50.80K61.60K57.50K42.10K27.90K77.00K010.00K10.00K15.00K055.00K006.00K08.00K03.00K0000
Gross Profit -----------0007.20K2.27K16.00K36.56K42.40K49.50K27.90K17.10K59.40K05.50K6.00K8.21K039.00K003.60K04.80K01.80K0000
Operating Income -3.99K-3.60K-8.04K-3.63K-3.55K-6.99K-3.77K-3.73K-147.84K-209.25K-212.54K-240.85K-395.99K-295.00K-204.22K-314.83K-274.83K-250.70K-275.46K-273.42K-335.04K-214.26K-242.47K-303.94K-515.84K-833.44K-1.15M-1.79M-1.02M-1.11M-1.19M-1.54M-1.12M-1.63M-1.11M-1.66M-1.26M-1.27M-1.46M-1.56M
Net Income -5.74K-5.44K-10.02K-5.74K-5.75K-9.27K-6.27K-6.30K-147.84K-209.25K-214.51K-243.35K-886.36K-52.18K-7.59M-6.43M-1.57M-797.37K-88.23K-2.41M3.74M-1.84M394.85K27.84M-2.91M-1.84M-1.15M-1.79M-982.34K-1.05M-1.10M-1.45M-1.04M-1.56M-1.04M-1.64M-1.23M-1.24M-1.41M-1.51M
Diluted EPS ------------------0.12-0.010.000.00-0.010.1411.18-1.25-0.75-0.18-0.20-0.07---0.73-1.11-0.75-0.83-0.48-0.48-0.38-0.41
R&D Expense --------4.36K18.03K45.17K59.83K25.19K87.73K3.20K4.20K2.88K000--00059.18K10.00K659.70K230.94K319.03K309.48K992.72K422.39K924.75K581.80K743.30K501.26K465.15K541.66K459.20K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 00000004.80K124.40K165.50K164.50K87.75K88.60K9.00K11.00K6.00K
Gross Profit ------0-3.20K54.02K120.00K113.90K39.80K60.11K5.40K6.60K3.81K
Operating Income -14.29K-19.83K-20.10K-20.12K-19.43K-20.83K-759.67K-1.18M-1.11M-1.13M-1.11M-3.13M-10.24M-5.62M-5.74M-6.14M
Net Income -17.26K-24.05K-25.59K-27.28K-28.01K-30.76K-766.07K-2.66M-13.66M-8.48M-36.33M19.21M-10.14M-5.29M-5.49M-6.00M
Diluted EPS -----------62.695.61-0.93-3.76-3.71-2.52
R&D Expense ------85.33K260.08K96.62K00109.18K6.27M1.97M2.40M2.26M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -4143.10K1.57K37495449.60K322.51K203.15K477.16K530.80K717.77K11.27M19.19M10.72M6.67M7.81M
Total Equity --48.11K-72.16K-97.75K-125.03K-153.04K49.50K-157.79K-2.24M-3.99M-8.07M-39.80M10.22M15.86M10.34M6.34M7.51M
Cash & Equivalents 5754141.10K781374954100221.87K13.70K304.06K88.65K98.01K10.72M----
Long Term Debt --------493.25K--------
Total Liabilities ------100480.30K2.44M4.47M8.60M40.52M1.05M3.32M371.39K327.64K284.88K
Current Liabilities -48.52K75.27K99.32K125.41K154.00K100453.86K2.44M4.47M8.60M40.52M1.05M3.32M371.39K327.64K284.88K

Cash Flows (Annual)

Figures in USD.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -13.66K-13.96K-16.77K-22.91K-17.32K-14.64K-445.23K-889.62K-1.05M-1.21M-434.56K-2.22M-7.80M-8.03M-5.30M-5.86M
Investing Cash Flow 000000-10.00K0-0-250.00K0-10.08M3.45M6.32M-50.50K
Financing Cash Flow 13.50K14.65K16.45K22.50K17.90K13.90K677.00K681.45K1.34M997.68K693.92K12.84M15.47M-270.95K1.45M7.17M
Share Buybacks ------------0270.95K174.96K10.00K

Ratios (Annual)

Figures in %.

Metric Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------66.7%43.4%72.5%69.2%45.4%67.8%60.0%60.0%63.4%
Operating Margin % --------24,537.6%-895.7%-682.9%-677.7%-3,562.2%-11,562.5%-62,445.9%-52,216.9%-102,380.2%
Net Margin % --------55,398.1%-10,977.2%-5,126.1%-22,082.2%21,892.8%-11,449.3%-58,739.7%-49,940.7%-99,916.8%
ROE % 35.9%33.3%26.2%21.8%18.3%-62.1%485.5%118.9%341.8%105.1%91.3%188.0%-63.9%-51.1%-86.6%-79.8%
ROCE % 29.7%27.5%20.6%16.1%12.7%-42.1%578.3%52.8%27.9%14.0%2.8%-30.6%-64.6%-54.3%-90.6%-81.6%

Shareholding Pattern

Insiders
0.53%
Institutions
5.66%
Public Float
5.69%

Top Institutional Holders

#Holder% HeldSharesValue
1 Hudson Bay Capital Management Lp 2.05% 135.17K $130.56K
2 Anson Funds Management LP 1.60% 105.55K $101.95K
3 Armistice Capital, LLC 0.64% 42.00K $40.57K
4 Xtx Topco Ltd 0.40% 26.56K $25.65K
5 Geode Capital Management, LLC 0.39% 25.80K $24.92K
6 Vanguard Capital Management LLC 0.31% 20.35K $19.66K
7 Vanguard Fiduciary Trust Co 0.08% 5.52K $5.33K
8 Tower Research Capital LLC (TRC) 0.07% 4.85K $4.69K
9 Global Retirement Partners, LLC 0.06% 4.12K $3.98K
10 UBS Group AG 0.03% 2.06K $1.99K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for CELZ

Google News Mon, 03 Aug 2026

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. SEC Filing (Aug 3, 2026) | CELZ EFFECT - Stock Titan

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxORnVWVmRacExqcmtIMFFPNVROOG9qdlpfaW1nZk9lSmlSOU5TTkVkZWU4T3pMeUxCT1pPUDM2Nlp2RndsWllYRjlrSllHWjNZM2g0VlVmNktZWXF4REZWZDRUd1BJUjh4S0NrTUdYbjBDazJPdjgzb1J5WElGdXpXNFJOdWNMenpMaW1nZX…

Google News Fri, 26 Jun 2026

CELZ Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTFBQdjZKbVpuVU91bFZpa1BaT05PZzFJdFNENzljQk9NbVlYVkx2cUkzY0ZOU1NJNWoxNDBHa1BGSDNxMnhoSi1KalRxSXFmb2xPSjdkUlBHVlFiSnRUc2o0TGo1S09hMXlGc2tzOEtuRWxPeHlvR2F6dlV3?oc=5" target="_blank">CEL…

Google News hu, 09 Apr 2026

Analysts Expect Breakeven For Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Before Long - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxQTElwYTlpVVFTRVhmUkpxZDh0RUdUcUd3RnJwOEx3c0MtUml1ZkVSdktpcktqaFdja1pNS0RaaWxLaUtzVmw4RFJaUGdsaHJZWWQtWFNpTFREVThjcDB4NUdGUVV0WjlxcjVlSUE0YkNOSHFZNnRJUjBFOGZlb1d3Z3Brb1MzdXlmaFU5T1…

Google News ue, 30 Jun 2026

Creative Medical Technology Holdings surges as traders appear to chase recent clinical and platform updates - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxNaUFOcTk3RUFkZEl3OWN2RWtiUUJsd3YzZjBKdEFNbkNpeWhZTUo4bFZuTllXbFYyNGh4M2pMT2t0clNEN0ZrS2E3QjlJUDh2Q2laQWU3M2pENzVITFQtYTNBOWc1Y1I5WnM5c0JJT3d5RThPMmhNTHdZYnpodTdFeTJSbmpLSzRRTzRyZG…

Google News Wed, 27 May 2026

CELZ - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE8tYkwwbnoyRUhWdjdMVlNDVm9wMVdIUHp0Q2gwM3g2UzlYclVtVTVTZUtNS0QzNmtVNWF5VmpRWXFlTkg5blE?oc=5" target="_blank">CELZ</a>&nbsp;&nbsp;<font color="#6f6f6f">Finviz</font>…

Google News Fri, 26 Jun 2026

These Three Stocks Fell More Than 10% Today To Hit 52-Week Lows -- What's Driving The Investor Skepticism? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxQcV9uY1E4dHhORXFxMlhnVVVod21IWG9lRU5CdW9lclpDRGx4enMtMVg4c3pCVzBUeU9QaUIxU25raGcyNDdiM0tGRFdDU21ic1EzRHZtY0dudGZqZHdiN1FxWGlaNzNkNDhxQ0xyN0hGYXBsTTF0OVN6Vmx5VWpIbGtORFBQekZKWTZIRD…

CELZ — Frequently Asked Questions

What is the current share price of Creative Medical Technology Holdings, Inc. (CELZ)?

As of 2026-09-19 21:16 PDT, Creative Medical Technology Holdings, Inc. (CELZ) trades at $1.08 on NasdaqCM. Its 52-week range is $0.65 to $5.59.

What is the market capitalisation of CELZ?

Creative Medical Technology Holdings, Inc. (CELZ) has a market capitalisation of $7.12M on NasdaqCM.

What is the P/E ratio of CELZ?

CELZ trades at a trailing price-to-earnings (P/E) ratio of -0.53. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.78.

What is the return on equity (ROE) of CELZ?

CELZ has a return on equity (ROE) of -77.88%. Its return on capital employed (ROCE) is -81.64%.

Is CELZ a good stock to buy?

This page provides a data-driven analysis of Creative Medical Technology Holdings, Inc. (CELZ), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space